crossing96/oncoscreening huggingface dataset:
Perioperative Risk Factors for New-Onset Perioperative Atrial Fibrillation Following Minimally Invasive Esophagectomy: A Single-Center Retrospective Study.	BACKGROUND: Atrial fibrillation (AF) is the most common cardiovascular complication following esophagectomy. The aim of this study was to identify the risk factors for new-onset perioperative (intraoperative and/or postoperative) AF in patients undergoing minimally invasive esophagectomy (MIE). METHODS: This study used a single-center retrospective design and included 814 patients who were diagnosed with esophageal cancer and underwent McKeown MIE. The patients' characteristics and perioperative data were collected from the electronic medical records and analyzed. RESULTS: New-onset perioperative AF occurred in 5.3% of the patients (43/814), with 4 patients developing intraoperative AF and 39 patients developing postoperative AF. Multivariate logistic regression analysis identified age (odds ratio [OR] 1.081 and p < 0.001), history of coronary heart disease (OR 4.269 and p < 0.001), and intraoperative blood loss (OR 1.004 and p = 0.008) as independent risk factors for perioperative AF following MIE. The area under the receiver operating characteristic curve for the multivariate logistic regression model was 0.735 (95% confidence interval 0.660-0.810). The incidences of postoperative pulmonary complications and anastomotic leakage were significantly higher in patients with perioperative AF than in those without perioperative AF (both p = 0.011). Patients with perioperative AF also had a longer hospital stay (15.0 vs. 13.0 days and p = 0.034). CONCLUSIONS: Increasing age, history of coronary heart disease, and intraoperative blood loss were associated with new-onset perioperative AF following MIE. However, the impact of intraoperative blood loss on AF is likely to be of marginal clinical relevance. The observed AF fell below projected estimates, resulting in inadequate statistical power for the study outcomes. TRIAL REGISTRATION: Chinese Clinical Trial Registry (No. ChiCTR2300074003; date of registration, 27/07/2023).	esophagus
[Ag(2)Se nanoparticles suppress growth of murine esophageal cancer allograft in mice by eliminating Porphyromonas gingivalis].	OBJECTIVES: To investigate the efficacy of Ag(2)Se nanoparticles for eliminating intracellular Porphyromonas gingivalis (P. gingivalis) in esophageal cancer and examine the effect of P. gingivalis clearance on progression of esophageal cancer. METHODS: Ag(2)Se nanoparticles were synthesized via a chemical synthesis method. The effects of Ag(2)Se nanoparticles on P. gingivalis viability and colony-forming ability were assessed using fluorescence staining and colony formation assays. In a mouse model bearing subcutaneous murine esophageal cancer cell allograft with P. gingivalis infection, the effect of treatment with Ag(2)Se nanoparticles on the abundance of P. gingivalis in the tumor tissues was quantified using RNAscope in situ hybridization and quantitative polymerase chain reaction (qPCR), and the changes in tumor volume were monitored. The biosafety of Ag(2)Se nanoparticles was assessed by examining liver and kidney functions and pathological changes in the major organs of the mice. RESULTS: Transmission electron microscopy revealed that the synthesized Ag(2)Se nanoparticles were uniformly dispersed spherical particles with a diameter around 50 nm. In vitro experiments demonstrated that exposure to Ag(2)Se nanoparticles significantly reduced the viability and clonal proliferation capacity of P. gingivalis in a dose-dependent manner. In the tumor-bearing mice, treatment with Ag(2)Se nanoparticles significantly reduced the abundance of P. gingivalis in tumor tissues and suppressed tumor cell proliferation. No significant damages to the liver and kidney functions or the major organs were observed in Ag(2)Se nanoparticle-treated mice, demonstrating good biocompatibility of Ag(2)Se nanoparticles. CONCLUSIONS: Ag(2)Se nanoparticles exhibit significant bactericidal and inhibitory effects against P. gingivalis, and can effectively eliminate intracellular P. gingivalis to suppress the growth of esophageal cancer allograft in mice, suggesting the potential of Ag(2)Se nanoparticles in the treatment of esophageal cancer.	esophagus
Poly(I:C) signaling induces robust CXCL10 production and apoptosis in human esophageal squamous cell carcinoma cells.	We previously reported that high tumoral expression of Toll-like receptor 3 (TLR3) and CXCL10, a member of the CXC chemokine family, was an independent positive prognostic factor in patients with advanced thoracic esophageal squamous cell carcinoma (ESCC). However, the direct relationships between TLR3 and CXCL10 in ESCC cells was not fully understood. Here, we analyzed TLR3 mRNA and protein expression in two ESCC lines (TE8 and KYSE180) and one esophageal adenocarcinoma (EAC) line (OE19). We also assessed the effect of the TLR3 agonist poly(I:C) on production of downstream adapter proteins and cytokines, including CXCL10, and further tested its effects on cell viability and caspase 3/7 activity with and without siRNA-induced knockdown of TLR3 and the TICAM-1 or MAVS adapter protein. Both ESCC lines, but not the EAC line, showed high expression of TLR3 mRNA and protein. TICAM-1 and MAVS were also expressed, and their knockdown suppressed responsiveness to poly(I:C) in the ESCC lines. Poly(I:C) induced strong CXCL10 production, resulting in significantly upregulated caspase3/7 activity and downregulated cell proliferation in both ESCC lines but not the EAC line. The effect of poly(I:C) on CXCL10 production was attenuated after transfecting the cells with siRNAs targeting TICAM-1 or MAVS. TLR3 is thus highly expressed in ESCC cells, where it induces strong CXCL10 production and significantly upregulates caspase3/7 activity and downregulates cell proliferation. TLR3 signaling and the resultant downstream CXCL10 production have the potential to serve as useful prognostic markers and therapeutic targets for the treatment of ESCC.	esophagus
A nomogram for predicting cancer-specific survival in patients with locally advanced unresectable esophageal cancer: development and validation study.	BACKGROUND: Immunotherapy research for esophageal cancer is progressing rapidly, particularly for locally advanced unresectable cases. Despite these advances, the prognosis remains poor, and traditional staging systems like AJCC inadequately predict outcomes. This study aims to develop and validate a nomogram to predict cancer-specific survival (CSS) in these patients. METHODS: Clinicopathological and survival data for patients diagnosed between 2010 and 2021 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Patients were divided into a training cohort (70%) and a validation cohort (30%). Prognostic factors were identified using the Least Absolute Shrinkage and Selection Operator (LASSO) regression. A nomogram was constructed based on the training cohort and evaluated using the concordance index (C-index), net reclassification improvement (NRI), integrated discrimination improvement (IDI), calibration plots, and area under the receiver operating characteristic curve (AUC). Kaplan-Meier survival curves were used to validate the prognostic factors. RESULTS: The study included 4,258 patients, and LASSO-Cox regression identified 10 prognostic factors: age, marital status, tumor location, tumor size, pathological grade, T stage, American Joint Committee on Cancer (AJCC) stage, SEER stage, chemotherapy, and radiotherapy. The nomogram achieved a C-index of 0.660 (training set) and 0.653 (validation set), and 1-, 3-, and 5-year AUC values exceeded 0.65. Calibration curves showed a good fit, and decision curve analysis (DCA), IDI, and NRI indicated that the nomogram outperformed traditional AJCC staging in predicting prognosis. CONCLUSIONS: We developed and validated an effective nomogram model for predicting CSS in patients with locally advanced unresectable esophageal cancer. This model demonstrated significantly superior predictive performance compared to the traditional AJCC staging system. Future research should focus on integrating emerging biomarkers, such as PD-L1 expression and tumor mutational burden (TMB), into prognostic models to enhance their predictive accuracy and adapt to the evolving landscape of immunotherapy in esophageal cancer management.	esophagus
Identifying Hepsin as a novel biomarker for human esophageal squamous cell carcinoma (ESCC) and its application in fluorescence imaging.	Human Esophageal squamous cell carcinoma (ESCC) represents a type of malignant tumor characterized by a high mortality rate and a generally poor surgical prognosis. The accurate labeling and high-specificity visualization of ESCC cells is extremely importance for its precise diagnosis and effective treatment. Fluorescence molecular imaging has emerged as one of the most critical modalities for cancer detection and therapeutic guidance, owing to its superior sensitivity, cost-effectiveness, portability, real-time imaging, and no damage. In this study, we initially verified that Hepsin, a protease, is highly expressed in ESCC through high-throughput immunocapture (HIC) and Western blot (WB) assays. Subsequently, we designed and synthesized an innovative activatable fluorescent probe, Ac-KQLR Rhodamine 110. It is specifically identified and cleaved by Hepsin, which is over-expressed in ESCC cells. Consequently, the Ac-KQLR Rhodamine 110 could be utilized for the activation fluorescence imaging of ESCC cells, providing a method for their precise visualization. In conclusion, this research highlights that the overexpression of Hepsin serves as a novel biomarker for ESCC. Based on Hepsin's high expression in ESCC, our team has developed a distinctive activation fluorescence imaging strategy that can be employed for the tracking and identification of ESCC. The implementation of this strategy could potentially revolutionize the current methodologies used for monitoring and treating cancer, thereby offering new hope and improved outcomes for patients diagnosed with ESCC.	esophagus
Association between ERAS protocol and major postoperative complications and reasons for non-compliance in patients with esophageal cancer.	"INTRODUCTION: The association between each Enhanced Recovery After Surgery (ERAS) component and the incidence of major postoperative complications following Ivor Lewis or McKeown surgery is understudied. Therefore, we wanted to determine the association between ERAS components, major postoperative complications, and the reasons for non-compliance with the ERAS program. METHODS: Data were extracted from the prospective ERAS Registry managed by the University of Verona, Italy. We searched and compared the data for postoperative major complications (Clavien-Dindo Classification ≥3B) and reasons for non-compliance with 15 ERAS items in patients undergoing Ivor Lewis or McKeown surgery with radical intent for esophageal or esophagogastric junction cancer. RESULTS: The study sample was 346 patients: 43 (12.4 %) experienced one or more postoperative major complications. When stratified by type of surgery, complications were more frequent after McKeown surgery than after Ivor Lewis surgery (15.5 % and 11.5 %, respectively). Organizational setbacks were the most common reason for non-compliance with the ERAS program. We identified several associations between clinical and patient demographic characteristics and 90-day postsurgical complications. The multivariate model indicated an association between fewer major postoperative complications after Ivor Lewis surgery and adherence to the protocol items ""soft diet intake"" (adjusted odds ratio [OR], 0.23; 95 % confidence interval [CI], 0.08-0.63) and ""urinary catheter removal"" (adjusted OR, 0.26; 95 % CI, 0.10-0.63). DISCUSSION/CONCLUSIONS: Major complications are relatively frequent, especially after McKeown surgery. What remains uncertain is whether ERAS items can predict the occurrence of postoperative complications. Adherence to the protocol may be influenced by the co-occurrence of complications, comorbidities, and organizational setbacks."	esophagus
Treatment strategy and clinical outcomes of thoracoscopic endoscopic cooperative surgery for submucosal tumors in the esophagus.	PURPOSE: Recently, submucosal tumors (SMTs) of the esophagus have been treated with peroral endoscopic tumor resection (POET) and a new procedure called thoracoscopic endoscopic cooperative surgery (TECS). This study aimed to validate the treatment strategy for SMTs and determine whether or not TECS is a viable option when POET is not feasible. METHODS: POET and TECS were performed in 12 patients between February 2020 and January 2024. The clinical characteristics and perioperative outcomes were retrospectively evaluated. RESULTS: Six patients were included in each group, with most of the tumors located in the middle thoracic esophagus (75%). The general anesthesia duration was significantly longer in the TECS group than in the POET group (P < 0.001), but no significant differences in endoscopic procedure time, tumor mass index, oral intake date, or length of hospital stay were observed between the two groups. En bloc and R0 resections were performed in all patients. One patient in the TECS group experienced a Clavien-Dindo grade 3a adverse event, and no tumor recurrence occurred during the median follow-up period of 33 (range, 6-53) months. CONCLUSION: TECS is a safe and feasible option for SMTs when POET is difficult to perform.	esophagus
Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Patients After Esophagectomy.	Background: Patients with esophageal cancer (EC) who have undergone esophagectomy are at risk of developing hypoxemia and encountering postoperative complications. It is essential to ascertain whether the high-flow nasal cannula (HFNC) therapy offers superior clinical efficacy compared to conventional oxygen therapy (COT). Methods: Clinical data from 80 patients who experienced hypoxemia subsequent to radical esophagectomy were retrospectively collected at our institution spanning January 2020 to December 2022. The whole cohort was divided into two groups: the HFNC group and the COT group. Following oxygen administration, we evaluated the variations in arterial blood gas parameters and infection indices within each group, in addition to scrutinizing the occurrence of postoperative pulmonary complications. Results: The HFNC group was associated with a better oxygenation index (F (group)=41.779, p < 0.001) and partial pressure of carbon dioxide (F (group)=16.760, p < 0.001) compared with the COT group. Moreover, there were statistically significant differences in the reduction of C-reactive protein (F (group) = 17.603, p < 0.001) and neutrophil count (F (group) = 4.395, p=0.039) in the HFNC group compared with the COT group after 3 days of oxygen therapy. Notably, patients treated with HFNC exhibited a markedly reduced risk of developing postoperative complications, especially pneumonia (p=0.039). Conclusion: HFNC outperformed COT in enhancing oxygenation and reducing carbon dioxide levels and infection indices among patients with hypoxemia after radical resection of EC and also lowered the risk of postoperative pneumonia.	esophagus
Associations between vascular endothelial growth factor polymorphisms and response to 5-FU-based pharmaceutical therapy in esophageal squamous cell carcinoma: A meta-analysis.	BACKGROUND AND AIMS: Vascular endothelial growth factor (VEGF) gene polymorphisms are associated with the response to pharmaceutical therapy in many cancers. This study aimed to investigate the effects of VEGF gene polymorphisms in esophageal squamous cell carcinoma patients receiving pharmaceutical therapy. METHODS: This literature-based meta-analysis was performed with keywords related to VEGF gene polymorphisms and clinical response in esophageal squamous carcinoma patients receiving pharmaceutical therapy (including 5-FU, cisplatin, oxaliplatin, and calcium folinate). After a series of bias grading analyses and DerSimonian-Laird method analysis, odds ratios and 95% confidence intervals were calculated to examine the potential relationships. Sensitivity and subgroup analyses were subsequently performed to determine the major causes of heterogeneity. RESULTS: Heterogeneity was dramatically reduced after the removal of one study from the analysis (I(2) = 37%, P = 0.19). The remaining studies involved 5-FU-based treatment. The presence of VEGF G-1154A and VEGF-634C/G was found to be correlated with patient response to 5-FU/CDDP-based treatment, whereas VEGF-2549I/D was correlated with response to 5-FU/oxaliplatin-based treatment, and VEGF-936C/T was associated with both 5-FU/CDDP- and 5-FU/oxaliplatin-based treatment response. CONCLUSION: VEGF gene polymorphisms affect the response of esophageal squamous carcinoma patients receiving pharmaceutical therapy, especially 5-FU-based treatments.	esophagus
Attentive feature interaction based persistent homology-augmented network for esophageal cancer lesion detection.	BACKGROUND: Detecting lesions in esophageal cancer (EC) is important in guiding subsequent treatment. Deep learning methods based on convolutional neural networks (CNNs) and vision transformer (ViT) have made remarkable strides in the field of medical image analysis due to their powerful representational capabilities. However, without prior knowledge, both traditional CNNs and ViTs are susceptible to disregarding critical anatomical information, including loops and voids. The current methods, combined with persistent homology (PH), have been proposed to address certain limitations, but they neglect the inconsistencies among features caused by the lack of interaction between features, ultimately leading to a reduction in the model's generalization ability. PURPOSE: To address these challenges, we propose a novel framework, combined with PH and feature interaction, for identifying EC lesions from 3D CT images. The goal is to enhance the predictive capability of existing deep learning models by incorporating both topological information from PH and effective feature interaction mechanisms. METHODS: We applied cube-wise classification techniques to improve the detection of lesions associated with EC. The proposed framework consists of two fundamental modules: (1) persistence diagram cross-attention encoder (PDCAE) that completely encodes the persistence diagram (PD) created by PH through cross-attention. (2) recalibration guidance module (RGM) connecting the PH features with the image features efficiently to remove inconsistencies. RESULTS: The experimental results show that the proposed modules significantly enhance the predictive capability of standard backbone networks, and outperform the state-of-the-art classification network. CONCLUSIONS: This work highlights the potential of combining topological data analysis with deep learning for medical image analysis tasks. More potential downstream tasks that can utilize topological relationships remain to be explored in the future.	esophagus
The Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score as an Independent Prognostic Factor for Esophageal Cancer Patients who Received Curative Treatment.	BACKGROUND/AIM: Esophageal cancer (EC) is a malignant tumor with poor prognosis. Prognostic factors that may be used in the treatment and management of EC are important. The purpose of this study was to evaluate the impact of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score on the long-term oncological prognosis of patients with EC who have undergone curative treatment. PATIENTS AND METHODS: Patients with EC who underwent curative resection at Yokohama City University between 2000 and 2020 were included. Clinical data were retrospectively retrieved from medical records and analyzed. The HALP score was determined as follows: HALP=[hemoglobin (g/l)×albumin (g/l)×lymphocytes (/l)]/platelets (/l). Kaplan-Meier method and Cox regression model were used to assess the overall (OS) and recurrence-free survival (RFS) and to evaluate the prognostic value of the HALP score. RESULTS: In total, 180 patients were included in this study. They were classified into the HALP-low (n=110) and HALP-high (n=70) groups using a cutoff value of 40. The 5-year OS rate was 46.9% in the HALP-low group and 66.0% in the HALP-high group (p=0.012). The 5-year RFS rate was 31.1% in the HALP-low group and 51.4% in the HALP-high group (p=0.006). The HALP score was found to be an independent prognostic factor for OS [odds ratio (OR)=1.954, 95% confidence interval (CI)=1.157-3.299, p=0.012] and RFS (OR=1.852, 95% CI=1.197-2.866, p=0.006). CONCLUSION: The HALP score is a factor that predicts the oncological prognosis in patients with EC who have undergone radical resection.	esophagus
Intraoperative Fluorescent Imaging with Indocyanine Green during Thoracoscopic Esophagectomy with Subcarinal Lymph Node Dissection for Esophageal Cancer with a Right Superior Pulmonary Vein Anomaly: A Case Report and Literature Review.	A 68-year-old woman was diagnosed with clinical T3N1M0 middle thoracic esophageal cancer. Preoperative three-dimensional computed tomography indicated a right superior posterior pulmonary vein (RSPPV) anomaly, which ran behind the right intermediate bronchus. The patient underwent thoracoscopic esophagectomy with mediastinal lymph node (LN) dissection. Before we began the dissection of the right subcarinal LN, we administered indocyanine green intravenously to confirm the running position of the anomalous RSPPV, and we were able to ascertain its placement accurately with correct recognition of the difference between the blood vessels and surrounding tissue. Although the patient had LN metastasis adjacent to this anomalous vessel and the dissection procedure was tough due to tightly adhesion, intraoperative fluorescent imaging enabled us to perform the dissection without any superfluous vascular injury. Intraoperative fluorescent imaging is very useful in such cases, providing accurate intraoperative information on the location of the anomaly and facilitating safer surgery.	esophagus
Synchronous carcinomas of the esophagus: Influence of prognosis and staging.	OBJECTIVE: Synchronous carcinomas of the esophagus (SCEs), occurring at multiple locations in the esophagus or the esophagogastric junction, are uncommon. In this study, we retrospectively analyzed patients with SCEs, focusing on the types of SCEs and their influence on staging and prognosis. METHODS: Data of patients treated surgically for esophageal carcinoma between January 2009 and January 2016 were retrieved from the database in the thoracic surgery department of our hospital. The clinicopathologic features of SCEs were collected. The factors on TNM staging and prognosis of SCEs were also analyzed. RESULTS: A total of 103 patients (2.8 %) with SCEs were found among 3662 consecutive patients. Based on the features of multiple carcinomas, 13 patients (0.35 %) exhibited intramural skip metastasis and 90 patients (2.46 %) displayed multiple primary carcinomas (MPCs). Patients with single esophageal cancer were propensity-matched at a ratio of 1:2 as control group. Among the patients with MPCs, tumor B was defined as the relatively early or superficial lesion. The 5-year OS of patients with MPCs with Tumor B (T1b/2) vs. matched group was 35.0 % vs. 48.45 % respectively (P = 0.013). For the N-stage of SCEs, a revised N-staging system, based on the number of involved lymph node stations better separated sub-N-stage survival curves (P = 0.002), compared with the conventional system (P = 0.019). CONCLUSIONS: For the pT-stage evaluation of MPCs, the second tumor should be taken into consideration. The revised N-staging system could better reflect the lymph node metastatic characteristics and predict survival in SCEs.	esophagus